The inventor of the groundbreaking Crispr gene-editing technology is skeptical about artificial intelligence replacing human effort in the realm of scientific discovery, adding to a growing debate over its ...
Formation Bio CEO Ben Liu is convinced that drug discovery isn’t the bottleneck in getting medicines to market—it’s going through clinical trials.
Now he’s raised some $615 million from top ...
Researchers at OpenAI and Ginkgo Bioworks showed that an AI model working with an autonomous lab can design and iterate real biology experiments at unprecedented speed.
OpenAI’s GPT can summarize ...
Silicon Valley long salivated at the prospect of disrupting America’s medical system. The country spends some $5trn a year on health care, about a fifth of its GDP and twice as ...
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer Jennifer Doudna wants to build an entire ecosystem to bring ...
TIME's flagship AI newsletter spotlighted Formation Bio CEO Ben Liu and the company's contrarian approach to AI in pharma. While much of the industry has focused on using AI ...
In a deal that Noetik’s leaders call a new paradigm for AI-focused biotech, GSK is paying millions to license AI models rather than drug candidates.
The British pharma giant is ...
Noetik, an AI-native biotech company pioneering self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics, announced today a five-year strategic collaboration and AI model licensing agreement ...
Biology voices weigh in on the impact of AI on drug discovery from the largest NeurIPS research conference to date.
More than 24,000 machine learning experts gathered for the largest ...
In 2017, fresh off a PhD on theoretical chemistry, John Jumper heard rumors that Google DeepMind had moved on from building AI that played games with superhuman skill and was starting ...
What if the genome you were born with wasn’t fixed? Eric Kelsic, CEO of Dyno Therapeutics, explains how gene therapy is moving from promise to reality, delivering treatments directly ...
Joe Betts-LaCroix's startup is preparing for its first clinical trial — a pivotal milestone in its war on age-related disease.
For Joe Betts-LaCroix, the answer to every problem seems to ...
Thermal Clients Formation Bio and Georgiamune Named to Fierce Biotech's 2025 Fierce 15
Thermal is proud to announce that clients Formation Bio and Georgiamune have been recognized as two of ...
...Tweaking proteins to do human bidding is nothing new. Enzymes and antibodies, for example, have long endured such outrages. But that is not what Dr Ennist is up to. ...
AI drug discovery and development companies have emerged as one of the hottest areas of the wide-ranging life sciences industry.
Why it matters: As AI-focused biotechs proliferate, VC investors and ...
During a visit to Lawrence Berkeley National Laboratory (Berkeley Lab), Secretary of Energy Chris Wright today announced a new contract with Dell Technologies to develop NERSC-10, the next flagship ...
Demis Hassabis is reshaping what’s possible in science. His work at DeepMind—most notably the development of AlphaFold, which earned him a share of the 2024 Nobel Prize in Chemistry—is ...
Retro Biosciences is raising a $1bn round to fund the artificial intelligence-powered biotech’s mission to increase human lifespan by a decade, starting by getting its first drug into trials ...
Roche’s exercise of its option concludes initial collaboration and further validates Dyno’s field-leading gene delivery platform and AI-powered sequence design technologies for therapeutic developers
Dyno to receive ...
Genesis Therapeutics started in now-a16z venture capitalist Vijay Pande’s lab at Stanford, where Genesis co-founder and CEO Evan Feinberg did his Ph.D. A16z led Genesis’ 2023 $200 million series B alongside ...
The genome-editing technology can be supercharged by artificial intelligence—and the results are already being felt.
In 2025, we will see AI and machine learning begin to amplify the impact of Crispr genome ...
Company’s first offering, Ataraxis Breast, clinically validated in landmark study to be 30% more accurate than the current standard of care for breast cancer
$4 million in seed ...
The treatment has the potential to cure diseases, but high costs and a difficult delivery process have held it back.
Roche Holding AG is willing to pay more than $1 billion to solve one ...
New strategic partnership leverages the power of the Dyno platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets
Dyno to receive US$50 million upfront cash ...
The technology’s promise can sound like science fiction—it might help us adapt to a radically different climate, or grow organs for people in need—but experts are also concerned about ...
Four years ago, Jennifer Doudna and Emmanuelle Charpentier shared the Nobel Prize in chemistry for the development of a method for genome editing called CRISPR-Cas9.
In her lecture, Doudna detailed “extraordinary and exciting opportunities” for the technology ...
How do we develop and integrate breakthrough health technology into our lives?
From robot helpers to smart prosthetics to "smart skin" to CRISPR gene editing, our ability to build a ...
RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by ...
New advancements in artificial intelligence have the capacity to deliver major breakthroughs in cancer therapy.
AI-powered protein design company Profluent used AI to make an open-source gene editor called OpenCRISPR-1.
OpenCRISPR-1 ...
Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.
To read of AI’s feats in ...
Much as ChatGPT generates poetry, a new A.I. system devises blueprints for microscopic mechanisms that can edit your DNA.
Generative A.I. technologies can write poetry and computer programs or create images of teddy ...
The most striking evidence that artificial intelligence can provide profound scientific breakthroughs came with the unveiling of a program called AlphaFold by Google DeepMind.
In 2016 researchers at the company ...
As OpenAI's CEO, Altman is widely considered to be the face of artificial intelligence, reprogramming the way we'll live and work for years to come. His relentless push into ...
Funding propels company’s proprietary platform consisting of Generative AI models and large-scale datasets purpose-built for designing and validating novel proteins, opening new frontiers in therapeutics and industrial applications
...
Venture capitalists are financing drugmakers seeking to improve upon today’s blockbuster weight-loss medications or combat their side effects.
New obesity medications have helped millions of people lose weight but can ...
BioAge Labs has reeled in the biotech industry’s largest private financing round so far in 2024 as the California startup goes full throttle on the hottest areas in obesity ...
Funding to advance Phase 2 clinical trials of azelaprag, an apelin receptor (APJ) agonist, in combination with Lilly’s Zepbound (tirzepatide) and therapeutic pipeline
Azelaprag improves metabolic and muscle ...
Joe Betts-LaCroix didn’t have time to wait for architects, construction workers or really any of the normal things that go into building a new office, let alone a new ...
Inceptive’s Jakob Uszkoreit, a pioneer of the technology behind ChatGPT, attracts Nvidia funding to design ‘biological software’.
A biotech start-up founded by a former Google artificial intelligence expert has raised ...
Jakob Uszkoreit, one of the people who laid the groundwork for generative platforms such as ChatGPT, has secured $100 million in a Series A raise for an AI biotech ...
